Skip to content

Search

Showing results for "Study of bullying"

‘Nicotine-free’ e-juice samples found to contain nicotine and harmful chemicals

Six out of ten ‘nicotine-free’ e-cigarette liquids analysed by The Kids Research Institute Australia researchers contained nicotine as well as an acutely toxic chemical typically found in pesticides and disinfectants.

Research to explore promising new RSV treatment supported by innovation seed funding

Researchers from the Wal-yan Respiratory Research Centre are collaborating with Virex Pharma to undertake vital research into a potential breakthrough treatment for RSV infections in young children, thanks to a $499,241 grant awarded by the WA Department of Health Innovation Seed Fund.

Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy

The cure rate for pediatric patients with B precursor acute lymphoblastic leukemia (pre-B ALL) is steadily improving, however relapses do occur despite...

Young adults with intellectual disability transitioning from school to post-school: A literature review framed within the ICF

The purpose of this review was to describe literature relating to transition for young people with an intellectual disability and identify knowledge base gaps.

The dystroglycan receptor maintains glioma stem cells in the vascular niche

These findings reveal a central role of the DG receptor, not only as a structural element, but also as a critical factor promoting mesenchymal-like GBM

Australia’s first Indigenous scientist appointed to CSIRO board

The Kids Research Institute Australia and Australian National University Professor of Indigenous Genomics, Professor Alex Brown, has become the first Indigenous member of the Commonwealth Scientific and Industrial Research Organisation (CSIRO) Board.

Company behind device that improves drug delivery to lungs awarded prestigious innovation award

A The Kids Research Institute Australia spin-off company, Inspiring Holdings Pty Ltd (Inspiring), has been announced as winner of the Wesfarmers Wellbeing Platinum Award in the prestigious WA Innovator of the Year awards for their novel Universal Spacer System – a device which improves the delivery of inhaled dru

FDA-approved disulfiram as a novel treatment for aggressive leukemia

Acute leukemia continues to be a major cause of death from disease worldwide and current chemotherapeutic agents are associated with significant morbidity in survivors. While better and safer treatments for acute leukemia are urgently needed, standard drug development pipelines are lengthy and drug repurposing therefore provides a promising approach.

Community Priority setting for Fetal Alcohol Spectrum Disorder Research in Australia

Introduction Fetal Alcohol Spectrum Disorder (FASD) is a neurodevelopmental disorder caused by prenatal alcohol exposure (PAE). FASD research is a rapidly growing field that crosses multiple disciplines. To ensure research is relevant and meaningful for people living with FASD, their families, and the broader public there is a need to engage community members in setting priorities for research.

Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells

Both tumour suppressive and oncogenic functions have been reported for dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A). Herein, we performed a detailed investigation to delineate the role of DYRK1A in glioblastoma. Our phosphoproteomic and mechanistic studies show that DYRK1A induces degradation of cyclin B by phosphorylating CDC23, which is necessary for the function of the anaphase-promoting complex, a ubiquitin ligase that degrades mitotic proteins.